Drug intelligence / Profile preview

reboxetine + oxybutynin

Development stage: Phase 3
Lead developer: Apnimed
Modality: Small Molecules
Administration: Oral

Overview

AD128 is an investigational oral pharmaceutical combination therapy under development for the treatment of obstructive sleep apnea. It consists of reboxetine, a selective norepinephrine reuptake inhibitor, and oxybutynin, a selective antimuscarinic agent. The drug is designed to target the neurologic control of upper airway muscles during sleep, aiming to maintain airway patency in patients with obstructive sleep apnea. AD128 is being developed by Apnimed and has been evaluated in clinical trials for its efficacy in reducing the severity of obstructive sleep apnea[1][2][3][4].

Brand names: Edronax + Ditropan
Other names: AD128AD-128AD 128

Targets

NET (Norepinephrine Transporter)CHRM3 (M3)CHRM2 (M2)M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on reboxetine + oxybutynin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on reboxetine + oxybutynin.

Explore the full profile